Clinical Profile and Treatment Outcome of H (Isoniazid) Mono Resistant Pulmonary Tuberculosis Patients at Tertiary Health Care Center in South Gujarat
International Journal of Current Pharmaceutical Review and Research · 30.06.2026 · 18 (06)
DOI: 10.25258/ijcpr.18.6.9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.06.2026. Verfasst von Nilkanthchandra S. Chaudhari und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Tuberculosis is a preventable and curable disease. In 2022, TB was the world’s second leading cause of death from a single infectious agent. Isoniazid is the first line medicine for the treatment of active tuberculosis and latent TB infection, with high bactericidal activity. Resistance to isoniazid reduces the effectiveness of TB treatment and increases the risk of acquiring resistance to other first line drugs. This leads to increase risk of multidrug resistant TB. Aim and objectives: The objective is to study clinical profile and treatment outcome in isoniazid mono resistant pulmonary TB under programmatic conditions. Materials and Methods: This study is a prospective, observational and longitudinal single center study performed at the tertiary health care center in South Gujarat (DRTB NODAL Center). Diagnosed isoniazid (mono- H) resistant pulmonary tuberculosis patients during study period were enrolled and followed up during study to record demographic data, clinical characteristics and treatment outcomes.
Results
In our study, 30 patients of isoniazid mono resistance pulmonary TB were enrolled. The mean age of patients was 36.7 years. Two-third of the patients were male (70%). 63.3% of patients were underweight (BMI < 18.5 kg/m2 ). All patients presented with symptoms of cough, fever and anorexia. Primary H mono resistant was detected in 83.3% patients. Most common INH mutation detected on FL-LPA was in the Kat G gene in 60% patients followed by InhA gene in 36.7% patients and one patient had both gene mutation. The most common ADRs observed were gastritis and GIT symptoms (43.3%). In our study favorable outcomes with treatment regimen as per national program guidelines was observed in 28 (93.34%) patients. Unfavorable outcome was observed in form of treatment failure in 1 patient and death in 1 patient.
Conclusion
Most of isoniazid mono resistant TB patients present with primary resistance to isoniazid. Patients who have microbiologically confirmed TB with rifampicin sensitive need to be checked for FL-LPA for isoniazid sensitivity. The availability of rapid diagnostic test and treatment regimen under national program is effective for diagnosis and management of H mono resistant TB.
Zitieren
APA
Chaudhari, N. S., Shamaliya, K., Patel, R., & Vadgama, P. (2026). Clinical Profile and Treatment Outcome of H (Isoniazid) Mono Resistant Pulmonary Tuberculosis Patients at Tertiary Health Care Center in South Gujarat. International Journal of Current Pharmaceutical Review and Research, 18(06). https://doi.org/10.25258/ijcpr.18.6.9
Vancouver
Chaudhari NS, Shamaliya K, Patel R, Vadgama P. Clinical Profile and Treatment Outcome of H (Isoniazid) Mono Resistant Pulmonary Tuberculosis Patients at Tertiary Health Care Center in South Gujarat. International Journal of Current Pharmaceutical Review and Research. 2026;18(06). doi:10.25258/ijcpr.18.6.9
BibTeX
@article{Chaudhari2026,
author = {Chaudhari, Nilkanthchandra S. and Shamaliya, Khyati and Patel, Robinkumar and Vadgama, Parul},
title = {Clinical Profile and Treatment Outcome of H (Isoniazid) Mono Resistant Pulmonary Tuberculosis Patients at Tertiary Health Care Center in South Gujarat},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {06},
doi = {10.25258/ijcpr.18.6.9}
}
EUVIMED